01 / DESIGN
What was studied?
A 68-week randomized trial enrolled 338 adults with overweight or obesity without diabetes. The active semaglutide and liraglutide comparison was open-label, while matched placebo comparisons were blinded. Lifestyle counseling accompanied the interventions.
02 / FINDINGS
What did the researchers report?
Average body-weight reduction was greater in the semaglutide active group than in the liraglutide active group. The publication also compared weight-loss thresholds and adverse-event profiles.
03 / LIMITS
How should it be interpreted?
The open-label active comparison, differences in trial regimens and discontinuation rules belong in the interpretation. This does not establish a universal ranking across every population or formulation. Pharmaceutical trial results should not be assigned to laboratory catalog materials.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.